In this study we evaluated the cytotoxic effects of the XPO1 inhibitor selinexor, used in combination with chemotherapy drugs or the PI3Kδ inhibitor idelalisib in CLL. Here, XPO1 is linked to B-cell chronic lymphocytic leukemia.